SILO PHARMA, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
SILO PHARMA, INC. (SILO) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 2.00 million shares for the 3-month period ending 2018-03-31, per its 10-Q filed 2019-05-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2019-05-14
- SILO PHARMA, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2018-03-31 was 2.00M shares.
- SILO PHARMA, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2017 was 2.00M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|
| 2018-03-31 | 2.00M shares 10-Q · filed 2019-05-14 | |
| 2017-12-31 | 2.00M shares 10-K · filed 2019-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |